AI assistant
Sending…
Lite Strategy, Inc. — Director's Dealing 2021
Jul 7, 2021
34267_dirs_2021-07-06_5cce7f74-0cd9-478d-a061-f777a79adbda.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: MEI Pharma, Inc. (MEIP)
CIK: 0001262104
Period of Report: 2021-07-01
Reporting Person: HOWSON TAMAR D (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-07-01 | Stock Option (Right to Buy) | $2.95 | A | 50000 | Acquired | 2031-07-01 | Common Stock (50000) | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $2.52 | 2029-07-01 | Common Stock (60000) | 60000 | Direct |
| Stock Option (Right to Buy) | $3.49 | 2030-07-02 | Common Stock (50000) | 50000 | Direct |
Footnotes
F1: The options will vest in equal monthly installments over twelve months.
F2: 40,000 of the options vested on July 1, 2020, and are currently exercisable and 20,000 options will vest in equal monthly installments over thirty-six months beginning July 1, 2019.
F3: All of such options are presently exercisable.
More from Lite Strategy, Inc.
Regulatory Filings
2026
May 13
Interim / Quarterly Report
2026
May 13
Regulatory Filings
2026
Feb 17
Interim / Quarterly Report
2026
Feb 17
Director's Dealing
2026
Feb 12
Regulatory Filings
2026
Feb 12
Annual Report
2025
Dec 30
Regulatory Filings
2025
Dec 30
Proxy Solicitation & Information Statement
2025
Dec 30
Regulatory Filings
2025
Dec 30